HR
LYRA

Howe & Rusling’s LYRA THERAPEUTICS INC LYRA Stock Holding History

Howe & Rusling’s Portfolio LYRA Stock Details LYRA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-2
Closed – – 1139
2022
Q2 		$0 Buy
+2
New +$544 ﹤0.01% 1120

Other funds holding LYRA

PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
PVI
Pura Vida Investments New York $14.9M AUM 38.76% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
CC
Clearline Capital New York $1.93B AUM 38.13% 1-Year Est. Return

Howe & Rusling's LYRA Position: Q3 2022 in Review

Howe & Rusling sold out of LYRA THERAPEUTICS INC (LYRA) in Q3 2022, closing a stake of 2 shares.

Howe & Rusling first reported a position in LYRA in Q2 2022 and held it in 1 quarter. The position peaked at $0 in Q2 2022. 37 funds tracked by Wall St. Rank hold LYRA as of Q3 2022.

  • Howe & Rusling reported no remaining LYRA THERAPEUTICS INC position as of Q3 2022 after selling out during the quarter.
  • Howe & Rusling sold 2 LYRA THERAPEUTICS INC shares in Q3 2022.
  • Howe & Rusling first reported a position in LYRA THERAPEUTICS INC in Q2 2022 and held it in 1 quarter.
  • Howe & Rusling's LYRA THERAPEUTICS INC position peaked at $0 in Q2 2022.
  • 37 funds tracked by Wall St. Rank held LYRA THERAPEUTICS INC as of Q3 2022.

Based on Howe & Rusling's 13F filing for Q3 2022, filed 14 Nov 2022.